A
Andrew M. L. Lever
Researcher at University of Cambridge
Publications - 221
Citations - 8461
Andrew M. L. Lever is an academic researcher from University of Cambridge. The author has contributed to research in topics: RNA & Virus. The author has an hindex of 45, co-authored 219 publications receiving 7502 citations. Previous affiliations of Andrew M. L. Lever include United Arab Emirates University & Royal Free Hospital.
Papers
More filters
Journal ArticleDOI
Sepsis: definition, epidemiology, and diagnosis
TL;DR: On 29 March 2005 a 41 year old journalist died of sepsis six days after a minor surgical procedure; she had consulted eight doctors over the intervening Easter bank holiday weekend, and the coroner pointed out that non-recognition of the seriousness of her condition contributed to her death.
Journal ArticleDOI
Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions.
TL;DR: Sequences required for efficient packaging of human immunodeficiency virus type 1 (HIV-1) genome RNA into virus particles were identified and deletion of 19 base pairs resulted in a virus markedly attenuated for replication in human T lymphocytes.
Journal ArticleDOI
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation
Ravindra K. Gupta,Sultan Abdul-Jawad,Laura E. McCoy,Hoi Ping Mok,Dimitra Peppa,Maria Salgado,Javier Martinez-Picado,Javier Martinez-Picado,Monique Nijhuis,Annemarie M. J. Wensing,Helen Lee,Paul Grant,Eleni Nastouli,Jonathan Lambert,M Pace,Fanny Salasc,Christopher Monit,Andrew J. Innes,Andrew J. Innes,Luke Muir,Laura Waters,John Frater,Andrew M. L. Lever,Andrew M. L. Lever,Simon Edwards,Ian H Gabriel,Ian H Gabriel,Eduardo Olavarria,Eduardo Olavarria +28 more
TL;DR: It is suggested that a single allogeneic HSCT with homozygous CCR5Δ32 donor cells may be sufficient to achieve HIV-1 remission with reduced intensity conditioning and no irradiation, and the findings provide further support for the development of HIV- 1 remission strategies based on preventing CCR 5 expression.
Journal ArticleDOI
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7.
Bo Meng,Steven Kemp,Steven Kemp,Guido Papa,Rawlings Datir,Isabella Ferreira,Sara Marelli,William T. Harvey,Spyros Lytras,Ahmed Mohamed,Giulia Gallo,Nazia Thakur,Dami A. Collier,Dami A. Collier,Petra Mlcochova,Lidia M. Duncan,Alessandro M Carabelli,Julia C. Kenyon,Julia C. Kenyon,Andrew M. L. Lever,Andrew M. L. Lever,Anna De Marco,Christian Saliba,Katja Culap,Elisabetta Cameroni,Nicholas J Matheson,Nicholas J Matheson,Luca Piccoli,Davide Corti,Leo C. James,David Robertson,Dalan Bailey,Ravindra K. Gupta +32 more
Posted ContentDOI
Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ΔH69/V70
Steven Kemp,Steven Kemp,Bo Meng,Isabella Ferreira,Rawlings Datir,William T. Harvey,Dami A. Collier,Dami A. Collier,Guido Papa,Alessandro Carabelii,Spyros Lytras,Julia Kenyon,Julia Kenyon,Andrew M. L. Lever,Andrew M. L. Lever,Leo C. James,David Robertson,Ravindra K. Gupta +17 more
TL;DR: Recurrent emergence and significant onward transmission of a six-nucleotide out of frame deletion in the S gene, which results in loss of two amino acids: H69 and V70 is reported, which likely acts as a permissive mutation that allows acquisition of otherwise deleterious immune escape mutations.